Influence of hemoglobin level and dose of administered recombinant human beta erythropoietin on survival of hemodialysis patients | Zendy

Violeta Knežević | Zendy; Aleksandra Milošević | Zendy; S Vodopivec | Zendy; Dusan Bozic | Zendy; Ivana Budošan | Zendy; Milena Majic | Zendy

Open Access

Influence of hemoglobin level and dose of administered recombinant human beta erythropoietin on survival of hemodialysis patients

Author(s) -

Violeta Knežević,

Aleksandra Milošević,

S Vodopivec,

Dusan Bozic,

Ivana Budošan,

Milena Majic

Publication year - 2011

Publication title -

vojnosanitetski pregled

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.123

H-Index - 19

eISSN - 2406-0720

pISSN - 0042-8450

DOI - 10.2298/vsp1109749k

Subject(s) - erythropoietin , medicine , hemodialysis , dialysis , hematocrit , hemoglobin , nephrology , analysis of variance , gastroenterology , anemia

In patients with end-stage renal disease, treatment with erythropoietin lowers cardiovascular morbidity, improves quality of life and patient survival. The aim of this study was to determine the difference in survival of hemodialysis patients treated with recombinant human beta erythropoietin and patients without this treatment, and to determine the influence of hemoglobin level and erythropoietin dose on the survival of these patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research